The present invention discloses novel piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonistic activity. Specifically, the present invention discloses a compound represented by the formula (I), a pharmaceutically acceptable salt or a solvate thereof:
wherein
A is substituted or unsubstituted monocyclic aryl or monocyclic heterocyclyl; X is a single bond or C(=O); Y is a single bond, CR5R6NR7 or C (=O) NR7; R1 and R2 are independently hydrogen or substituted or unsubstituted alkyl; R3 is substituted or unsubstituted aryl or heterocyclyl; R4 is halogen, substituted or unsubstituted alkyl, alkoxy, aryloxy or heterocyclyloxy, etc.; p is an integer of 0 to 2; q is 0 or 1; m is 0 or 1; n is an integer of 0 to 5; and B is aromatic carbocycle, monocyclic heterocycle or bicyclic fused hetero ring.
本发明公开了具有 NPY Y5 受体拮抗活性的新型
哌啶和
吡咯烷衍
生物。具体而言,本发明公开了由式(I)代表的化合物、其药学上可接受的盐或溶液:
其中
A 是取代或未取代的单环芳基或单环杂环基;X 是单键或 C(=O);Y 是单键、CR5R6NR7 或 C(=O)NR7;R1 和 R2 独立地是
氢或取代或未取代的烷基;R3 是取代或未取代的芳基或杂环基;R4 是卤素、取代或未取代的烷基、烷
氧基、芳
氧基或杂环
氧基等。p 是 0 至 2 的整数;q 是 0 或 1;m 是 0 或 1;n 是 0 至 5 的整数;B 是芳香
碳环、单环杂环或双环融合杂环。